Susan G. Arbuck
101 works · 53,400 citations · h-index 44
Top works
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Accelerated Titration Designs for Phase I Clinical Trials in Oncology
- Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
- New guidelines to evaluate the response to treatment in solid tumors
- Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
- Taxol: the first of the taxanes, an important new class of antitumor agents.
- Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
- Taxol®: science and applications.
- Flow cytometric analysis of DNA aneuploidy in primary and metastatic human solid tumors,
- Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial.
- A reassessment of cardiac toxicity associated with Taxol.
- Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
- Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
- Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
- Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
- A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma.
- Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia
- Overview of chemotherapy for pancreatic cancer